Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Depreciation and Depletion (2016 - 2021)

Kiora Pharmaceuticals' Depreciation and Depletion history spans 7 years, with the latest figure at $4786.0 for Q4 2021.

  • For Q4 2021, Depreciation and Depletion rose 70.56% year-over-year to $4786.0; the TTM value through Dec 2021 reached $20296.0, up 141.65%, while the annual FY2025 figure was $25000.0, 400.0% up from the prior year.
  • Depreciation and Depletion reached $4786.0 in Q4 2021 per KPRX's latest filing, roughly flat from $4807.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $9633.0 in Q3 2018 to a low of $817.0 in Q1 2020.
  • Average Depreciation and Depletion over 5 years is $5344.4, with a median of $5243.5 recorded in 2017.
  • Peak YoY movement for Depreciation and Depletion: surged 5300.0% in 2017, then tumbled 87.75% in 2020.
  • A 5-year view of Depreciation and Depletion shows it stood at $5680.0 in 2017, then rose by 17.41% to $6669.0 in 2018, then dropped by 0.01% to $6668.0 in 2019, then tumbled by 57.92% to $2806.0 in 2020, then soared by 70.56% to $4786.0 in 2021.
  • Per Business Quant, the three most recent readings for KPRX's Depreciation and Depletion are $4786.0 (Q4 2021), $4807.0 (Q3 2021), and $6354.0 (Q2 2021).